Makers Laboratories Ltd Downgraded to Sell Amid Valuation and Financial Concerns

Valuation Shift: From Attractive to Fair

The most significant trigger for the downgrade is the change in Makers Laboratories’ valuation grade. Previously rated as attractive, the valuation has now been reassessed as fair. The company’s price-to-earnings (PE) ratio stands at 38.57, which, while lower than some peers, remains elevated relative to historical norms. The price-to-book value is 1.24, indicating the stock is trading slightly above its net asset value but not at a compelling discount.

Enterprise value to EBITDA (EV/EBITDA) is 5.74, which is moderate but reflects a cautious stance given the company’s earnings volatility. Comparatively, peers such as Bliss GVS Pharma and Kwality Pharma are classified as very expensive with PE ratios above 40 and EV/EBITDA multiples exceeding 24, placing Makers Labs in a relatively better but still cautious valuation bracket.

Return on capital employed (ROCE) at 15.26% is respectable, yet the return on equity (ROE) is low at 3.22%, signalling limited profitability on shareholders’ funds. This disparity between ROCE and ROE highlights inefficiencies in capital utilisation and shareholder returns, contributing to the fair valuation assessment.

Financial Trend: Mixed Signals Amid Weak Long-Term Growth

Financially, Makers Laboratories posted positive quarterly results for Q4 FY25-26, with net sales reaching a record ₹35.75 crores and PBDIT hitting ₹5.27 crores. The company also reported a strong debtors turnover ratio of 7.08 times, indicating efficient receivables management. However, these short-term gains are overshadowed by a weak long-term fundamental trend.

Operating profits have declined at a compound annual growth rate (CAGR) of -7.99% over the past five years, signalling deteriorating operational efficiency. Additionally, the average ROE over this period is a modest 4.67%, reflecting low profitability per unit of equity. Over the last year, despite a 2.37% stock return, profits have plunged by 71.7%, underscoring volatility and underlying weakness in earnings quality.

Quality Assessment: Weak Long-Term Fundamentals

The quality of Makers Laboratories’ business remains a concern. Despite being part of the Pharmaceuticals & Biotechnology sector, the company’s micro-cap status and low profitability metrics weigh heavily on its investment appeal. The average ROE of 4.67% over five years is significantly below industry standards, indicating limited value creation for shareholders.

Moreover, the company’s operating profit decline at nearly 8% CAGR over five years reflects challenges in sustaining growth and operational efficiency. While the recent quarter showed some improvement, these are isolated gains rather than a reversal of the long-term trend. The stock’s Mojo Score of 47.0 and a Mojo Grade of Sell further reinforce the cautious stance, downgraded from a previous Hold rating on 14 July 2026.

Technical Indicators: Modest Price Movement Amid Volatility

Technically, Makers Laboratories’ stock price has shown mixed performance relative to the broader market. Over the past week, the stock gained 2.27%, outperforming the Sensex which declined by 1.44%. Year-to-date, the stock has delivered a robust 29.92% return compared to a negative 9.58% for the Sensex, suggesting some resilience.

However, over longer horizons, the stock’s performance is less impressive. The one-year return is a modest 2.37%, lagging the Sensex’s -6.32%, and the five-year return is negative at -21.60%, while the Sensex gained 45.65%. The 52-week price range of ₹109.00 to ₹186.70 indicates significant volatility, with the current price near ₹153.50, reflecting a discount from the high but above the low.

These technical factors, combined with valuation and fundamental concerns, have contributed to the downgrade in the investment rating.

Peer Comparison and Market Context

Within the Pharmaceuticals & Biotechnology sector, Makers Laboratories is positioned as a micro-cap with a market cap grade reflecting its smaller size and associated risks. Compared to peers such as Bliss GVS Pharma, Kwality Pharma, and Hester Biosciences, which are rated very expensive, Makers Labs’ valuation appears more reasonable but is still not compelling enough to warrant a Buy rating.

Its PEG ratio of zero indicates no meaningful growth premium, contrasting with peers that have PEG ratios ranging from 0.14 to 2.09, signalling expectations of growth priced into those stocks. The company’s dividend yield is not available, which may deter income-focused investors.

Despite some operational improvements, the weak long-term growth trajectory and low profitability metrics suggest that Makers Laboratories faces structural challenges that limit its investment appeal at current levels.

Conclusion: Cautious Outlook Amid Mixed Signals

The downgrade of Makers Laboratories Ltd from Hold to Sell reflects a comprehensive reassessment of its investment merits. While recent quarterly results showed some positive momentum, the company’s valuation has shifted from attractive to fair, driven by modest profitability and subdued long-term growth prospects.

Financial trends reveal a concerning decline in operating profits over five years and low returns on equity, signalling weak fundamental strength. Technical indicators show mixed price performance with volatility and limited upside relative to the broader market.

Investors should approach Makers Laboratories with caution, considering the availability of better-valued and higher-quality alternatives within the pharmaceuticals sector and beyond. The current Mojo Grade of Sell and a score of 47.0 underscore the need for prudence in portfolio allocation.

Shareholding and Market Position

The company remains majority-owned by promoters, which can provide stability but also limits free float liquidity. The stock’s trading range between ₹109.00 and ₹186.70 over the past year reflects investor uncertainty amid sectoral and company-specific challenges.

Given these factors, the downgrade aligns with a cautious investment stance, prioritising capital preservation and seeking opportunities with stronger fundamentals and clearer growth trajectories.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →